

Disclosures

None financial

- It's hard to get rich doing vulvar disorders

I'm not a dermatologist!

- I just see a lot of this
 So I read a lot about this
- So I do a lot of this!

Objectives

- Recognize and describe normal vulvar anatomy (including variants)
- Recognize and/or treat benign vulvar disease
- Recognize and work-up non-benign vulvar disease
- Be familiar and comfortable with workup and treatment of common complaints/findings
- Be comfortable with typical and atypical presentations of common office vulvar complaints

This presentation will...


- Serve as an introduction
- Be as high yield as I can make it!!
- LOTS OF PICTURES! <u>Not</u> be inclusive (TOO MUCH OUT THERE!)
- Casual! (Speak up and ask questions, please)
 There may be some bad puns (sorry)



Typical Day

39yo F presents for annual exam. No significant PMHx. Last Pap 3 years ago, normal. Reports itching and intermittent vaginal discharge. Wants refill on OCPs.









Key to recognizing abnormal, is to know and understand normal anatomy and variations!

Vulvar Exam: Key points

- Be methodical!
- Have the right tools available (and know how to use them)!
- Look and touch!
- Always have good exposure!







Vulvar Anatomy


Nonhair-bearing Mucus membrane similar to mouth

vs Hair-bearing similar to rest of skin














6





Classification




Figure 1. The three types of labial hypertrophy encountered in the study.


Smarrito, Stéphane. "Classification of Labia Minora Hypertrophy: A Retrospective Study of 100 Patient Cases." JPRAS Open, vol. 13, 17 June 2017, pp. 81–91., dol:10.1016/j.jpra.2017.05.013.















Disease vs Normal

- Guard against over-diagnosis
- Significant morbidity from overly aggressive treatment of low-grade disease and of equivocal changes
- Most common normal vulvar findings that have been misdiagnosed as disease are
 Micropapillations
 vascular ectasia
 sebaceous hyperplasia





Micropapillomatosis Labialis

- Tiny papillary growths on the vestibule
- Usually symmetric
- May turn acetowhite
- Not HPV-related
- NORMAL variant!






Courtesy of Tom Cox, MD


Micropapillations


- Biopsies often reported as HPV
 - HPV-DNA not routinely assoc.
 - If biopsy done, may be ideal to do insitu hybridization as well as hematoxylin-eosin stains
- Three patterns: micropapillae, vestibular papillomatosis, and papillary HPV disease



Courtesy of Dr. Hope Haefner







Common vulvar variations

Hyperpigmentation



- Typically of labial minora and perianal skin
- Pregnancy, hormones and women with darker skin tones

Terminology: How to speak the language


- Primary morphology
- Secondary morphology
- Pigmentation (Coloration)
- Shapes
- Distribution

Primary Morphology

- Macule
- Patch
- Papule
- Plaque
- Wheal
- Vesicle
 Bulla
 Pustule


Nodule

• Tumor























15



Basic principles of diagnosis

- Differentiate "itch" vs "hurt"
- Wet mount for EVERY chronic symptom
- Biopsy and culture liberally and as needed
- Ask the patient questions!
- ASK THE PATIENT QUESTIONS!
- ASK THE PATIENT QUESTIONS!!

| Systematic Approach to Common Vulvar Disorders | | | | | |
|--|---|--|--|--|--|
| Ulcers | Behcet's syndrome, AIDS, HSV, Syphilis, Hidradenitis | | | | |
| Papules/Masses | Papillomatosis, Molluscum, Condyloma, Sebaceous Hyperplasia, Nevi, Achrochordons, Angiokeratomas | | | | |
| Cysts | Bartholin, Mucous, Skene | | | | |
| Neoplastic Lesions | VIN, Paget's, SCC, Melanoma | | | | |
| Skin conditions | Psoriasis, Lichen Planus | | | | |
| Dermatoses | Contact, Metals, others | | | | |
| | | | | | |




Basics of biopsy

- Biopsy is <u>NOT OBJECTIVE</u>
- TELL the pathologist what you want to know
- A negative biopsy doesn't rule out disease
- Repeat biopsies may be useful
- Avoid midline/skin folds Don't squash/crush
- specimen!
- Off steroids for 3-4 weeks ideal



Punch Biopsy Anesthesia

- 1% lidocaine (sodium bicarb) 27-30 gauge needle to inject 1-3 cc's of anesthetic agent
- Inject subepidermally
- 3-5 mm Keyes punch
- Fine suture (3.0 or 4.0)
 - Hemostasis & ↓ pain
 - Monsel's/Silver nitrate slows healing



Punch Biopsy Technique

- Select a punch of sufficient size to obtain adequate tissue while minimizing scar size
 - 3 mm punch for most - 4 mm minimum if histology and
 - immunostaining
- A punch that is slightly larger than the lesion can remove the entire lesion



Punch Biopsy Technique

- Perform an intradermal injection for anesthesia
- Prep the skin with isopropol alcohol, povidone-iodine or chlorhexidine solution - Alcohol prep pad is usually sufficient



Punch Biopsy Technique

- Make the defect oval or elliptical by stretching the skin perpendicular to the lines of least skin tension with the nondominant hand
- After the biopsy, relax the nondominant hand, and the circular defect becomes more oval



Punch Biopsy Technique

- Rotate the punch with mild downward force
- Turn the blade back-and-forth around its center axis
- Stop as soon as skin is penetrated and feel a "give"
 - Don't go to the hub except where the skin is thick with no underlying structures




Punch Biopsy Technique

Lift the specimen with forceps or the anesthesia needle

 Cut it free at the base (beneath dermis) if necessary





Vulvar therapy/care

Vulva reacts more intensely to irritants


Cleansing


- Plain tepid water (never hot) with fingertips!
- Pat dry, never hair dryer
- Hypoallergenic soaps i<u>f must</u>

Steroid Pointers

- Start strong, then work down
- Limit amount (15grams without refills)
- Vulvar trigone = steroid resistant
- Labiocrural fold/perianal area steroid sensistive
- Very inflamed tissue try systemic first!

| Madscapen www.medscape.com | | |
|------------------------------------|---|-----------------------------|
| Class | Genetic Name | Formelation |
| Class 1 Very High Potency | | |
| | Betamethasone dipropionate | 0.05% G O (dorstene) |
| | Cipbetanol | 0.05% CFGLO |
| | Difforasone diacetate | 0.05% 0 |
| | Halobetasol propionate | 0.05% C O |
| Class 2 High Potency | | |
| Control 1 registre controls | Ameinonide | 0.1% 0 |
| | Betamethasone denopionate | 0.05% C (dprokene) |
| | Descrimetasone | 0.05% O, 0.25% C O |
| | Fluocinonide | 205% CO O S |
| | Hakinoride | 0.1% C |
| | Mometasone furcate | 0.1% 0 |
| | Microetasone furcate | 21%0 |
| Class 3 High Potency | | 01% C L |
| | Amelnonide | |
| | Betamethasone dipropionate | 0.05% C (non-diprolene) |
| | Betamethasone valerate | 0.1% 0 |
| | Desocimetasone | 0.05% C |
| | Difforasone diacetate | 0.05% C |
| | F lutic a some propionate | 0.005% 0 |
| | Hakinonide | 0.1% 0.5 |
| | Triamcingione | 0.1% 0 |
| Class 4 Mid Potency | | |
| | Betamethasone valerate | 0.12% F |
| | Flucinolone acetonide | 0.029% O |
| | Flurindrenolde | 0.05% 0 |
| | Hydrocordisone valerade | 0.2% 0 |
| | Mometasone futuale | 0.1% C |
| | Triamcingione | 0.1% C |
| Class 5 Mid Potency | That Carlor and | 0.1810 |
| CERES 5 Mill Potency | | |
| | Betamethasone dipropionate Retamethasone valente | 0.05% L 0.1% C |
| | | 0.1% C 0.025% C |
| | f lucinolone acetonide | |
| | If lutic a sorve proption alle | 0.05% C |
| | F luran drenolide | 0.05% C |
| | Hydrocortisone butyrate | 0.1% C |
| | Hydrocortisone valerate | 0.2% C |
| Class 6 Low Potency | | |
| | Alcometasone diorcolonate | 0.05% C O |
| | Retargethascos valetate | 0.1% L |
| | Descride | 0.05% CLO |
| | Flucingione acetonide | 0.01% C S |
| Class 7 Low Potency | | |
| Character Contractions | Hydrocordisone acetate | 0.5% CLO. 1% C OF |
| | | |
| | Hydrocortisone hydrochiotide | 0.25% CL 0.5% CLO 8. |
| | | 1% C LO 8, 2% L 2.5% C LO 8 |
| | | |
| C = Cream, F = Foam, G = Gel L = L | | |






Things that go ITCH in the night







Lichen Sclerosus Prevalence

- ~1:300 to 1:1000 in consulting clinics
- 1.7% among gynecologist
- Almost 3% in nursing homes
- 15% have extragenital disease
- 3-5% develop SCC
- Bimodal age distribution: 5th-6th decades and prepubertal girls
- Probably primarily autoimmune
- Associated with thyroid disease, estrogen
- deficiency, vitiligo, LP and psoriasis Stockdale CK, Boardman L. Diagnosis and Treatment of Dermatoses. Obstet Gynecol. 2018 Feb;131(2):371-386



Lichen Sclerosus - Symptoms

- Itch 90% severe 30-50%
- 10% no symptoms!Pain, burning, sore 40%
- Pain, burning, sole 40%
- Dyspareunia, sexual dysfunction
- Painful defecation, especially children
- With asymptomatic vulvar scarring look for LS





Lichen Sclerosus - Clinical Changes - Primary

- Classic white or waxy papules and plaques
- Cellophane-like surface sheen, crinkled, atrophic - Skin becomes thin and inelastic
- Figure of eight / hourglass pattern
- Usually starts at clitoral hood and/or perineal body Patterns variable (perianal in 30% women)
- Texture change touch it!!
- NOT in the vagina (unless on a prolapse)
- Rare in the mouth

Lichen Sclerosus Diagnosis

- Biopsy is recommended (except in children)
- Serology is not useful
- A brief evaluation including thyroid function tests and examination for vitiligo and alopecia should be considered

ale CK, Boardman L. Diagnosis and Treatment of Vulvar oses. Obstet Gynecol. 2018 Feb;131(2):371-386.



Typically LS not


erosive or ulcerated unless


irritated / scratched, infected or carcinoma
















TREATMENT

 Treated with topical fluorinated steroids (clobetasol 0.05%)

 Treat only areas involved, and taper as disease improves



- Reduce to 2-3x/week
- Or less potent steroid



Lichen Sclerosus Treatment

- Use topical estrogen if possible for postmenopausal women
- Lifelong treatment
- Treatment with corticosteroids decreases risk of scarring and cancer

Stop the itching! Scratching proliferates the disease

JAMA Dermatol. 2015 Oct;151(10):1061-7

Lichen Sclerosus - Alternate Treatments

- Calcineurin inhibitors: burn, less effective
- Intralesional triamcinolone 3.3 10 mg/ml
- Systemic corticosteroids prednisone, IM triamcinolone
- Methotrexate 10 -15 mg/ week po or sc + folate 1 mg/d
- Other acetretin, cyclosporine, uv light, photodynamic therapy, Fraxel Laser, Platelet Rich Plasma

Evidence-based (53) Guideline on (anogenital) Lichen sclerosus. Kirtschig G, Becker J Eur Acad Dermatol Venereol. 2015 Oct;29(10):e1-43.



Intralesional Triamcinolone

Sites of Injections of T/C 2.5-10mg/ml 25 gauge needle





4-5% Risk SCC 60% Vulvar SCC have LS

Squamous Cell Carcinoma (in LS)









Lichen Planus

(I'm not going to spend much time here)

Lichen Planus

Onset is usually 30-60 years.

- 1% of population
- If buccal lesions present, 25% have vulvovaginal disease
- Related to cell -mediated immunity
- Complete control is not the norm
- Frustrating, chronic and recurring disease
- Punch biopsy for diagnosis
 Order histopathology and direct immunofluorescence to differentiate from other bullous disease
 - Andreassi L, Bilenchi R. Non-infectious inflammatory genital lesions. Clin Dermatol. 2014 Mar-Apr;32(2):307-14.

Lichen Planus

- Probably an autoimmune disorder with a T-cell-mediated pathogenesis
- Mucosal lichen planus most often affects the mouth, vulva, vagina, and rarely the conjunctiva, upper esophagus, and anus
- Mucous membrane lichen planus classically presents with white, reticulate, lacy or fern-like striae (Wickham's striae) adjacent to erythematous epithelium.
- Lichen planus can be difficult to distinguish from lichen sclerosus when presenting with a uniform white appearance

Stockdale CK, Boardman L, Diagnosis and Treatment of Vulvar Dermatoses. Obstet Gynecol. 2018 Feb;131(2):371-386.



Erosive Vulvovaginal LP

- Deep red erosions, glazed erythema with thin gray edge
- Fern-like or lacy white pattern
- Variable scarring / loss of architecturePain plus burning







LP Treatment is Challenging

- No single agent universally effective & prognosis poor.
- Topical application of ultrapotent topical steroid ointment (clobetasol 0.05%).
- Evidence based on small studies of oral rather than genital disease.
- Methotrexate, cyclosporine, oral steroids should be used only if local therapy fails.
- Surgery for vaginal synechiae and introital stenosis.

ACOG Practice Bulletin, No. 93. Obstet Gynecol 2008:111:1243.

Lichen Planus

- Affects usually postmenopausal women 50 60 yrs
- Sites Skin, scalp, nails
- Mucous membranes oral, genital, anus, esophageal, urinary tract
- Responds to immunosuppressive therapy

■ 2-5% → SCC

Always Examine the Vulva & Vagina & Mouth























SCC in Lichen planus









Lichen Simplex Chronicus

- Scratching feels good!
- NOT a primary condition!
- Worse with heat, humidity, stress and irritants
- Need to break the itch/scratch cycle
- May be unilateral!



Lichen Simplex Chronicus

Occurs in response to multiple inciting factors

- Genetics atopic dermatitis
- Environmental contact irritants (eg, irritation from clothing or chemicals in topical products, heat, perspiration)
- Infections (yeast, dermatophytes, bacterial)
- Chronic dermatologic conditions (psoriasis, lichen planus, lichen sclerosus)
- Neurologic disorders
- Psychiatric disorders
- From repetitive scratching/rubbing and self-excoriation tockdale CK, Boardman L. Diagnosis and Treatment of Vulvar Dermatoses. Obstet Gynecol. 2018 etr131(2):371-386.

Lichen Simplex Chronicus


- Nonscarring, chronic inflammatory disease of the skin
- In vulvar specialty clinics accounts for 10-35% of patientssuggesting a prevalence of ~ 0.5% in the U.S.
- May present at any age
- Iviay present at any age
- 65% 75% of patients have a history of allergic conditions (hay fever, asthma, childhood dermatitis)
- Often considered to be a localized atopic dermatitis
- Sleep disturbance from the unrelenting pruritus

Stockdale CK, Boardman L. Diagnosis and Treatment of Vulvar Dermatoses. Obstet Gynecol. 2018 Feb;131(2):371-386.

Lichen Simplex Chronicus

- Appears as erythematous, lichenified plaques +/- scaling or excoriation
- Skin changes
 - Areas that are thickened and leathery
 - Hperpigmented or hypopigmented
 - Chronic scratching can lead to erosions and ulcers
- Vaginal fungal cultures should be considered
- Biopsy is not necessary (but often done) unless there is concern for an underlying disease process or failure to respond to treatment

ckdale CK, Boardman L. Diagnosis and Treatment of Vulvar Dermatoses. Obstet Gynecol. 2018







Look for more than one problem



Contact +/-Infection +/-Dermatosis



Lichen Simplex Chronicus Treatment

- Multitargeted approach for optimal control of symptoms
 - Removal of initiating factor(s)
 - Repair of the skin's barrier function
 - Reduction of inflammation
- Disruption of the itch-scratch cycle
- Attention to vulvar hygiene and avoidance of irritants as well as barrier protection (eg, petrolatum, zinc oxide ointment)
- kdale CK, Boardman L. Diagnosis and Treatment of Vulvar Dermatoses. Obstet Gynecol. 2018 131(2):371-386.

Lichen Simplex Chronicus: Treatment

1) Optimize Epithelial Barrier function

- Control infection candida and bacteria (Staph, Strep)
- Reducing heat, sweat, irritation (oral oxybutynin ½ of 5 mg tab am and increase 2.5 mg up to 5 mg tid if needed)
- Stop irritants Stop excessive hygiene, menstrual cups
- Immediate therapy: Soak and seal
 - Sitz baths lukewarm water or normal saline (- 1 tbs salt / 3 cups water)
 - Use cool packs or compresses to deaden nerves _
 - No hot water No ice packs
- Use ointments ZnO2 Remove with plain mineral oil on soft tissue nan L. Diagnosis and Treatment of Vulvar Derm toses, Obstet Gynecol, 2018 CK Bos 121(2)-271 286

Lichen Simplex Chronicus: Treatment

- 2) Reduce Inflammation
- Moderate to high potency corticosteroid ointments
- Superpotent steroid taper -Clobetasol 0.05% ointment bid x 2 wks, daily x2 wks, MWF x 2 wks
- Systemic
 - Prednisone 40 mg qAM X 5 to 7 days then 20 mg qAM X 5 10 days then topical


 - IM Triamcinolone (Kenalog-40): 1mg/kg up to 80 mg/dose, repeat in 1-2 months if necessary

ockdale CK, Boardman L. Diagnosis and Treatment of Vulvar Dermatoses. Obstet Gynecol. 2018 b):131(2):371-386.

Lichen Simplex Chronicus: Treatment

- 3) Disruption of the itch-scratch cycle
- Night: antihistamine (10-25 mg hydroxyzine), 25 mg amitriptyline or doxepin 10-100 mg 2-3 hours pre-bedtime, and gabapentin - Non-sedating antihistamines work poorly
 - No topical diphenhydramine Sensitizer
- Day: fluoxetine, paroxetine, sertraline, citalopram (Celexa) 20 to 40 mg q AM - scratching can be a form of OCD
- Recognize and manage psychological factors
- Follow! Patients relapse
- Stop the scratching gloves, oven mitts, PJs

kdale CK, Boardman L. Diagnosis and Treatment of Vulvar Dermatoses. Obstet Gynecol. 2018 131(2):371-386



Bartholin's Gland Cyst / Abscess




Bartholin's Gland

's duct cyst and gland abs

- Located at base of labia minora
- Provide vaginal lubrication

n by Marcia Hartsock Simmons BJ, Hacker Y. Ma

- Ductal blockage results in enlargement
- Occurs in 2% of women
- Usually able to be treated in the office.



ess. Am Fam Physician. 2003;68(1):135.


Bartholin's Gland Cyst/Abscess

- More likely to occur in sexually active women - Friction during intercourse
- Abscesses usually E. Coli and Staph aureus - STDs have a role

these



- Treatment Don't lance/drain!
- They just come back Need to fistulize/marsupialize!
- Treat only if large, infected or patient
- symptomatic
- Biopsy?
 - Bartholin's cancer is rare (5% of vulvar cancers)
 - Higher >40, so biopsy if gland enlarged or recurrent obstruction
 - HPV 16 likes to live here





Word Catheter

- Inserted into the cyst or abscess following a stab incision
- Leave in place for 2-4 weeks
- Coverage for anaerobes & gonorrhea



Mayeaux EJ Jr. The Essential Guide to Primary Care Procedures 2nd edition. Philadelphia Wolters Kluwer; Lippincott, Williams, & Wilkins, 2015.





Molluscum Contagiosum-Tx

- Clinical course is usually self limited
 With no treatment, expect
 - resolution in 2-12 monthsIn immunocompetent kids, Tx
 - optional

den JC, vet al. Interv

ase Syst Rev. 2017 May 17;5:CD004767.

 Avoid treatments that cause scaring

ntions for cuta



Courtesy of Wikimedia Commons

Molluscum Contagiosum-Treatment

- Cryotherapy 1st line
- Cotton-tipped swab in liquid N2 applied for 6 to 10 seconds
 Scarring and hypopigmentation AEs
- Curettage 1st line physical removal - May require anesthetic
- Cantharidin 1st line physical removal
- Laser OK but expensive
- Imiquimod No better than placebo

van der Wouden JC, vet al. Interventions for cutaneous molluscum contagiosum. Cochrane Database Syst Rev. 2017 May 17;5:CD004767.

LSIL of vulva (Warts)

Diagnosis

– Usually clinical (appearance) – Biopsy if uncertain or suspect HSIL

 Treatment
 Based off size/location and symptoms, as well as patient

preference



LSIL of Vulva


- HPV 6 or 11 caused 90%
 - HPV 16, 18, 31, 33, and 35 are found occasionally as coinfections
 - Also associated with conjunctival, nasal, oral, and laryngeal warts
- Usually asymptomatic
 - Can be painful or pruritic

CDC. Sexually transmitted diseases treatment guidelines, 2010. MMWR . 2010 Dec 17;59 (RR-12):1-110.



| Treatment | Action | Side Effects | Response rate | Recurrence rate |
|------------------|---|---|-------------------|---------------------|
| TCA | Chemical coagulation of proteins | Pain, burning, local irritation | 51-81% | 36% |
| Podophyllin | Antimitotic agent: induces local tissue necrosis | Pain, local irritation | 45-77% | 13-100% |
| Imiquimod | Immune enhancer, stimulates local cytokine production | Redness, irritation, vesicles, hypopigmentation | 37-54% | 6-26% |
| Sinechatechin | Unclear – might be immune enhancer | Burning, pain, ulcerations, vesicular rash | 41-58% | 7-11% |
| Excision (knife) | | | 89-93% | 19-29% |
| (electrosurgery) | | | 94% | 14-22% |
| Laser Cryo | | | 60-100% 44-75% | Up to 77% 21-42% |
| | Courtesy of Colleen | K Stockdale, MD, MS | | |

| - | |
|---|--|
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |



Things that go OUCH in the night

Contact Dermatitis

- Most common cause of vulvar pruritis
- Allergic reaction is UNCOMMON
- Primary irritant is MOST COMMON
- Usually spares the folds
- Can occur with ANYONE (unlike allergy!)
- Often erosive/ulcerative



Common Irritants

- Body fluids
- Excessive bathingFeminine hygiene
- products
- Medications





Common Vulvar Irritants and Allergens

Adult or baby wipes

- Antiseptics (eg, povidone iodine, hexachlorophene) Body fluids (eg, semen or saliva)
- Colored or scented toilet paper
- Condoms (lubricant or spermicide) Topical antimycotics (eg. imidazoles, nystatin) Contraceptive creams, jellies, foams, nonoxynol-9, Lubricants

- Emollients (eg, lanolin, jojoba oil, glycerin)
- Laundry detergents, fabric softeners, and dryer sheets
- Rubber products (including latex)
- Sanitary products, including tampons, pads Soaps, bubble bath and salts, shampoos, conditioners

Stockdale CK, Boardman L. Diagnosis and Treatment of Vulvar Dermatoses. Obstet Gynecol. 2018 Feb;131(2):371-386.

Patient Counseling

Avoid (Vulvar Irritants and Allergens)

- Detergents
- Soaps
- Perfumes
- Many over-the-counter and prescribed topical medications
- (eg, anesthetics, steroids, antifungals, antibiotics)
- Douching; vaginal washing

Include (Routine Vulvar Care Measures)

Mild soaps, but avoid use on the vulva

Tea tree oil
 Topical anesthetics (eg, benzocaine, lidocaine, dibucaine)

Topical antibacterials (eg, neomycin, bacitracin, polymyxin)


Topical medications, including trichloracetic acid, 5-fluorouracil, podofilox or podophyllin

Vaginal hygiene products, including perfumes and deodorants

- Cleanse vulva with water only
- Gently pat the vulva dry after bathing
- Apply preservative-free emollient to hold moisture in the skin and improve barrier function
- Use pericare bottle to rinse after urination
- Use 100% cotton menstrual pads
- Use adequate lubrication for intercourse (silicone-based lubricants recommended)

Stockdale CK, Boardman L. Diagnosis and Treatment of Vulvar Dermatoree, Obstat Gunard, 2018 Edu;121(2):271,286








Genital HSV Infections

- Chronic, life-long viral infection HSV-1 and (mostly) HSV-2
- ~50 million persons in the U.S. infected with HSV-2
- Most persons infected have not been diagnosed
- Have mild / unrecognized infections but sometimes shed virus
- Majority of genital herpes infections transmitted by persons
- unaware that they have the infection or are asymptomatic
- 3 presentations
- Primary
- Non-primary, 1st episode
- Recurrent
- Workowski KA, Bolan GA. Sexually transmitted diseases treatment guidelines, 2015. MMWR Recomm

Genital Herpes Simplex - Clinical Manifestations

- Transmission through direct contact usually during asymptomatic shedding
- Primary infection commonly asymptomatic; symptomatic cases sometimes severe, prolonged, systemic manifestations
- \blacksquare Vesicles \Rightarrow painful ulcerations \Rightarrow crusting
- Recurrence potential

143



HSV Primary Infection

- Systemic symptoms may include fever, malaise, myalgia, and headache
- Symptoms last about
 2 weeks, healing 1-2 weeks, viral shedding 2-3 weeks



Norkowski KA, Bolan GA. Sexually transmitted diseases treatment guidelines, 2015. MMWR Recomm Rep. 2015 Jun 5;64(RR-03):1-137.

Recurrent HSV

- 50% prodrome
- Shorter time to healing
- Less viral shedding
- Less systemic symptoms
- Psychologically challenging



Workowski KA, Bolan GA. Sexually transmitted diseases treatment guidelines, 2015. MMWR Recomm

HSV Diagnosis

- Physical Exam: may have classical painful multiple vesicular or ulcerative lesions
- Confirmed by virologic or type-specific serologic tests
 - Cell culture and PCR are the preferred tests
 - PCR assays for HSV DNA are more sensitive and are most used
 - Failure to detect HSV by culture or PCR does not indicate an absence of HSV infection, because viral shedding intermittent
- Vorkowski KA, Bolan GA. Sexually transmitted diseases treatment guidelines, 2015. MMWR Recomm Rep. 2015 Jun 5;64(RR-03):1-137.

Herpes Simplex: Treatment

Local care/anesthetics (lidocaine)

- Gentle cleansing in genital region
 - Cetaphil lotion cleansers
 - Sitz baths
- Evaluate for other STDs!!
- Educate on natural history
 - ASHA Herpes Hotline 919-361-8488/ 800-227-8922

Herpes Simplex: Treatment Oral and Genital

- Antiviral therapy
 - Shortens duration of symptoms
 - No reduction frequency of recurrences
- Topical therapies
 - Reduce time to healing by at most 1 day
 - Symptomatic control

| HSV Trea | tment | | |
|---------------------------|--|--|-----------------------------------|
| Drug | Primary Infection Dosage | Recurrent Infection Dosage | Chronic Suppressive Therapy |
| Acyclovir (Zovirax) | 200 mg 5 times daily or 400 mg 3 times daily for 7-10 days | 800 mg twice daily for 5 days or 400 mg 3 times a day for 5 days** or 800 mg 3 times a day for 2-5 days | 400 mg PO twice daily* |
| Famciclovir (Famvir) | 250 mg 3 times daily for 10 days | 125 mg twice daily for 5 days*** or 1000 mg twice daily for 1 day or 500 mg once, followed by 250 mg twice daily for 2 days | 250 mg PO twice daily* |
| Valacyclovir (Valtrex) | 1 g twice daily for 10 days* | 500 mg twice daily for 3 days or 1 g once a day for 5 days** | 500 mg to 1 gram PO daily* |
| Workowsł | | **double the duration. ***500mg of the duration. ***500mg of the diseases treatment guidelines, 2015. MMW | |



Genital Herpes Simplex Tx: Chronic Suppression > 6 outbreaks/year

- Acyclovir (200 to 400mg bid)
 - 28-67% recurrence free for 12 months
 - 10 fold reduction in recurrence rate - 48% reduction in transmission rate b/w partners
 - 203-337 days median time 1st recurrence
- Famciclovir (250 mg BID PO)
- - time to first recurrence (120 versus 82 days with placebo) - free outbreaks (78 versus 42%)
- Valacyclovir (500 mg/day)
 - reduced frequency of recurrences 85%
- caution in immunosuppressed TTP/HUS Workowski KA, Bolan GA. Sexually transmitted diseases treatment guidelines, 2015. MMWR Recomm Rep. 2015. Jun 5.64(RR-03):1-137.

Chronic Suppression: Genital HSV

Tx

- Does not alter natural course of disease
- Continued asymptomatic shedding
- Decreased symptomatic partner 75% - Decreased partner seroconversion 48%
- Condom use reduces male to female transmission by 60-80%

Things that keep you up at night

(Psst, I'm talking about precancer/cancer)

SIL of vulv

Condyloma/HPV effect (6, 11)

HSIL of vu

- VIN usual type (warty, basaloid, etc)
 Carcinogenic HPV
- Differentiated VIN
- NOT associated with HPV
- Associated with other vulvar dermatoses

U.S. Genital HPV Statistics

- ■By age 50, ~75-80% of men and women will acquire genital HPV¹
 - -~6.2 million new infections/year1
 - -~20 million active infections²
- ■Highest prevalence = 20-24 year old ³
- \blacksquare High physical and emotional burdens with HPV infections and HPV-related diseases _4

| | Comm | on HPV Types |
|-----------|---|---|
| Туре | HPV Types | Disease Manifestations |
| High risk | 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68, 73, 82 | Low-& High-grade cervical changes ¹ Cervical cancer ^{1,2} Vulvar and Anal cancers ¹ Head and neck cancer ³ |
| Low risk | <mark>6, 11</mark> , 40, 42, 43, 44, 54, 61, 70, 72, 81 | Benign low-grade cervical changes ¹ Condylomata acuminata ¹ Recurrent respiratory papillomatosis ⁴ |
| | | |



Vulvar HSIL presentation/distribution

- Variety of colors
- white/brown/red
- Commonly raised (macular)
- Commonly multifocal
- Commonly found in non-hair bearing areas
- Can extend into vagina and to anus!










Risk Factors for Vulvar HSIL


- HPV (vulva, vagina, cervix)
- Cigarette smoking
- Immunosuppression
- Pregnancy
- HIV
- Autoimmune disordersDiabetes
- Transplant recipient - Chronic hepatitis
- Chemotherapy



Symptoms

- Most completely asymptomatic
- Itching or burning
- Irritation
- Dyspareunia





When to biopsy vulvar lesion?

Malignancy suspected

Non-healing ulcers
 Color variation
 Irregular borders/asymmetry
 If diagnosis cannot be made through
 visual inspection!


Persistent lesions that don't resolve with standard therapy


Resolve patient concerns
















| -(| Medical Treatment for HSIL Imiquimod 5% | |
|----|--|---|
| | Two to three times weekly for 12-16 weeks Colpo every 4-6 weeks during treatment - Excision for failures Pain and erythema may limit use | |
| -(| Cidofovir 1% | |
| | Response similar to Imiquimod in 2016 Cochrane review Hair bearing skin unresponsive. Tends to ulcerate | _ |
| -(| Photodynamic Therapy | |
| | ALA sensitizer + light = cell death Quality of evidence "poor" in 2016 Cochrane review | _ |



Vulvar HSIL (VIN usual type) Treatment

- Recommended for all women with HSIL
- Excision, laser ablation, or topical imiquimod (off-label use)
- Wide local excision should be performed if cancer is suspected
- Even if biopsies show vulvar HSIL
- Remain at risk of recurrent disease and cancer throughout their lifetimes Women with a complete response to therapy and no new lesions at followup visits scheduled 6 months and 12 months should be monitored by visual inspection of the vulva annually thereafter

Imiquimod 5%

- RTCs show topical imiquimod 5% is effective for vulvar HSIL
 Not approved by the U.S. FDA for this purpose
- \blacksquare 2-3 times weekly application to affected areas for minimum 12 weeks
 - Colposcopic assessment at 4-6-week intervals during treatment
- Residual lesions require surgical treatment
- Side Effects = Erythema and vulvar pain
- May have decreased effectiveness with immunocompromised

Post-Treatment Surveillance

Follow at 6 and 12 months, then yearly

ASCCP/ACOG Committee Opinion #675, Oct 2016

Follow Q6 months x 5 years, then yearly

Satmary W, et al. Gynecol Oncol (2017)

Follow Q3 months for 2-3 years, then Q 6 months

Best Practice and Research Clinical ObGyn 2014





RECAP

- Vulva is a host to many disease and is often ignored
- Thorough evaluation can improve patient satisfaction
-and save lives!
- It's interesting! (at least, to me)

RECAP

Education is vital!!

Explain disease processes and discuss expectations!!

Questions?